Trump Rattles Global Drugmakers With New 100% Tariff

President Donald Trump announced a 100% tariff on patented drugs, effective Wednesday, unless producers establish U.S. manufacturing plants, leading to a slump in European drugmakers like Novo Nordisk. This protectionist measure, part of broader industry-focused tariffs justified on national security grounds, threatens to significantly increase the cost of critical blockbuster treatments, including Ozempic and Mounjaro, which are largely produced abroad.

Analysis

A surprise announcement by President Donald Trump of a 100% tariff on patented drugs, effective Wednesday, has introduced significant and immediate risk to the global pharmaceutical sector. This protectionist measure, justified on national security grounds, specifically targets companies that do not have or are not building manufacturing plants in the US. The policy directly threatens the profitability of several blockbuster treatments, including Novo Nordisk’s Ozempic and Wegovy, Eli Lilly’s Mounjaro, and Johnson & Johnson's Stelara, as their production relies on facilities in countries like Denmark, Ireland, and Switzerland. The market's reaction was swift and negative, exemplified by a slump in European drugmakers, with Novo Nordisk shares falling by as much as 3.1%. This tariff forces a critical strategic decision upon affected firms: either absorb a potentially crippling cost, attempt to pass it on to consumers, or undertake a capital-intensive and lengthy process of on-shoring manufacturing to the United States.

Key Decisions for Investors

• Investors should immediately re-evaluate exposure to global pharmaceutical companies with significant US sales but ex-US manufacturing, particularly Novo Nordisk, Eli Lilly, and Johnson & Johnson, which are explicitly named as being at risk.
• Given that the announcement was made via social media without specifics, it is critical to monitor for official policy details, as any clarification on implementation, affected drug lists, or timelines could significantly alter the investment thesis for the sector.
• Consider the potential for relative outperformance in US-domiciled drug manufacturers or contract manufacturing organizations (CDMOs) that could benefit from a forced on-shoring of the pharmaceutical supply chain.
• Due to the high uncertainty and strongly negative sentiment, hedging or reducing overweight positions in the most exposed international drugmakers may be a prudent short-term strategy until the financial impact of the tariffs is clarified.